SS Innovations International (NASDAQ: SSII) is accelerating the global rollout of its SSi Mantra surgical robotic system, leveraging strong adoption in India to drive international expansion. The company reported 224 SSi Mantra systems installed across 12 countries and a 143% year-over-year increase in robotic procedures during the second quarter of 2026. Quarterly revenue rose 39% to $13.9 million, with system sales climbing 41% to $12.4 million, while installations reached 30 systems during the quarter.
A key demonstration of the system's capabilities occurred at Mohak Bariatrics and Robotics in Indore, India, where more than 50 robotic procedures were performed in a single day. This milestone underscores the growing utilization of the SSi Mantra platform in high-volume surgical settings. India remains the company's primary commercial market, but SS Innovations is actively pursuing regulatory expansion into Europe and the United States. CE marking is targeted for the end of 2026, and FDA review of its 510(k) application is now expected by the end of the first quarter of 2027.
Beyond regulatory milestones, SS Innovations is developing telesurgery capabilities and expanding surgeon training programs to drive further adoption. These initiatives aim to grow utilization and establish the platform in additional markets. The company's vision is to make robotic surgery affordable and accessible to a larger segment of the global population through its proprietary SSi Mantra system and comprehensive suite of SSi Mudra surgical instruments, which support a variety of procedures including cardiac surgery.
The implications of SS Innovations' progress are significant for the surgical robotics industry. As a cost-effective alternative to established players, the SSi Mantra system could democratize access to robotic surgery in emerging markets and beyond. The 143% increase in procedures indicates strong clinical adoption, which is critical for building trust among surgeons and hospitals. Moreover, the upcoming regulatory decisions in Europe and the U.S. could open substantial new revenue streams. If approved, SS Innovations would compete in the world's largest healthcare markets, potentially disrupting the dominance of current market leaders.
For investors, the company's financial performance and expansion plans offer a compelling growth narrative. The 39% revenue increase and 41% rise in system sales demonstrate commercial traction. However, regulatory risks remain, as delays or rejections could impact timelines. The company's focus on telesurgery also positions it at the forefront of an emerging trend that could revolutionize remote surgical care.
For more details, see the full article at https://ibn.fm/6FPBS. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. TechMediaWire, a specialized communications platform, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. The platform provides access to wire solutions via InvestorWire and editorial syndication to 5,000+ outlets.
